Administration of Signifor (Pasireotide) in Cushing's Disease
Signifor should be initiated at 0.6 mg or 0.9 mg subcutaneously twice daily, with dose titration every 2 weeks based on urinary free cortisol (UFC) response and tolerability, targeting eucortisolemia while carefully monitoring for hyperglycemia. 1
Initial Dosing Protocol
The FDA-approved starting dose is either 0.6 mg or 0.9 mg subcutaneously twice daily 1. However, certain patient populations require modified initiation:
- Elderly patients: Start at 1 mg twice daily with slow up-titration 2
- Hepatic impairment (Child-Pugh B): Start at 0.3 mg twice daily, maximum 0.6 mg twice daily 1
- Hepatic impairment (Child-Pugh C): Avoid use 1
- Asian patients: Consider lower starting dose (1 mg twice daily) due to 20% higher bioavailability 2
- Patients with impaired glucose metabolism: Start at lower dose 3
Administration Technique
Inject subcutaneously into the abdomen or top of thigh at approximately 45-degree angle 1. Key administration points:
- Administer with or without food 2
- Avoid injection sites showing inflammation or irritation 1
- Rotate injection sites; do not use the same site for 2 consecutive injections 1
- If a dose is missed, resume at the next scheduled time—do not double doses 1
Dose Titration Strategy
Assess treatment response every 1-2 weeks initially using UFC measurements 2. Maximum UFC reduction typically occurs by 2 months 1. The titration approach should be:
- For patients on 0.6 mg twice daily: Increase to 0.9 mg twice daily if well-tolerated and additional response needed 1
- Dose adjustments: Use 300 μg (0.3 mg) increments or decrements 2
- Maximum dose: 0.9 mg twice daily (60 mg/day total) 2, 1
- Minimum dose: 0.3 mg twice daily for sustained UFC normalization 2
For slow up-titration, increase the evening dose first to suppress overnight physiologic cortisol rise and reverse diurnal rhythm 2.
For severe hypercortisolism (baseline cortisol >36 mg/dL), consider starting at 6 mg/day with reassessment at 2-5 day intervals, though this requires more study 2.
Pre-Treatment Testing Requirements
Before initiating Signifor, obtain baseline assessments 1:
- Fasting plasma glucose (FPG) and HbA1c
- Liver function tests
- Electrocardiogram (ECG)
- Gallbladder ultrasound
- Serum potassium and magnesium levels
Optimize diabetes management intensively before starting treatment in patients with poorly controlled diabetes 1.
Monitoring During Treatment
Initially monitor UFC every 1-2 weeks, then extend to monthly once maintenance dose established 2. The evidence shows that approximately 40-54% of patients achieve UFC normalization 4, 3, 5.
Critical Safety Monitoring
Hyperglycemia is the most significant adverse effect, occurring in approximately 49-72% of patients 4, 6. However, this can be managed successfully in most cases, with <6% discontinuing due to hyperglycemia 3.
Monitor for:
- Hypocortisolism: May require dose reduction or temporary glucocorticoid supplementation 2
- QT prolongation: Periodic ECG monitoring, especially with concomitant QT-prolonging drugs 2
- Cholelithiasis: Periodic gallbladder monitoring 1
- Hypokalemia and edema: Common with 11β-hydroxylase inhibition 2
Drug Interactions
Pasireotide is a CYP3A4 substrate 2:
- With CYP3A4 inhibitors (ketoconazole, erythromycin, diltiazem): Decrease pasireotide dose
- With CYP3A4 inducers (mitotane, carbamazepine, rifampicin): Increase pasireotide dose
- Avoid or use cautiously with QT-prolonging drugs (citalopram, procainamide, levofloxacin) 2
- Washout period recommended when switching from ketoconazole or other CD medications 2
Clinical Outcomes Beyond UFC
Phase 3 trials demonstrated that pasireotide significantly reduces systolic and diastolic blood pressure, body weight, and LDL-cholesterol (-15 mg/dL) 4. Real-world data confirms improvements in cardiovascular parameters, with approximately 50% of patients showing improved blood pressure profiles and significant weight loss (>5% in 47% of cases) 7.
Common Pitfalls to Avoid
- Do not use immunoassays for cortisol monitoring due to cross-reactivity with 11-deoxycortisol; use tandem mass spectrometry 2
- Do not abruptly discontinue if hyperglycemia occurs; most cases are manageable with anti-diabetic therapy 3
- Do not ignore signs of adrenal insufficiency; counsel all patients on emergency glucocorticoid use 2
- Do not use in severe hepatic impairment (Child-Pugh C) 1
The evidence demonstrates that pasireotide provides sustained efficacy over 10+ years with manageable adverse effects when properly monitored 8, 9.